Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 3.35%356.65B | 3.76%1.42T | 3.98%363.57B | 3.50%367.5B | 4.37%348.65B | 3.19%345.1B | 2.16%1.37T | 2.09%349.65B | 3.07%355.08B | 2.71%334.05B |
Cost of revenue | 2.06%277.19B | 2.76%1.11T | 1.98%280.13B | 1.18%284.27B | 3.51%275.15B | 4.52%271.58B | 2.86%1.08T | 2.46%274.7B | 4.21%280.95B | 4.60%265.81B |
Gross profit | 8.09%79.47B | 7.46%313.69B | 11.33%83.44B | 12.27%83.23B | 7.72%73.5B | -1.46%73.52B | -0.34%291.92B | 0.76%74.95B | -1.03%74.13B | -4.05%68.24B |
Operating expense | 1.30%61.02B | 3.27%238.24B | 2.90%59.99B | 2.84%58.76B | 2.94%59.26B | 4.41%60.24B | 2.01%230.69B | 2.55%58.3B | 1.18%57.14B | 1.35%57.57B |
Operating profit | 38.86%18.45B | 23.22%75.45B | 40.83%23.45B | 44.01%24.47B | 33.51%14.25B | -21.49%13.28B | -8.32%61.23B | -5.02%16.65B | -7.79%16.99B | -25.49%10.67B |
Net non-operating interest income (expenses) | 3.29%2.39B | 246.22%367M | 4.33%-3.65B | 2.41%1.32B | 85.65%388M | 11.74%2.31B | 45.20%-251M | -4.87%-3.81B | 9.84%1.28B | 29.81%209M |
Non-operating interest income | 5.25%2.62B | 180.85%1.26B | 6.05%-3.42B | 6.22%1.56B | 67.91%628M | 11.00%2.49B | 62.09%449M | -5.36%-3.64B | 8.61%1.46B | 9.36%374M |
Non-operating interest expense | 30.56%235M | 27.71%894M | 30.73%234M | 33.33%240M | 45.45%240M | 2.27%180M | -4.76%700M | -4.28%179M | 0.56%180M | -8.84%165M |
Net investment income | -39.89%5.15B | 123.31%8.57B | ||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | -2.25%58.7B | 443.32%69.93B | 347.79%9.33B | -100.62%-68M | 479.75%619M | 1,501,100.00%60.05B | 6.21%12.87B | 60.93%2.08B | 10.95B | -163M |
Income from associates and other participating interests | 4.56%3.88B | 28.86%17.53B | 19.91%4.45B | 49.48%5.78B | 17.90%3.6B | 24.45%3.71B | 56.61%13.6B | 81.36%3.71B | 41.37%3.87B | 45.65%3.05B |
Special income (charges) | 2,456.00%10.01B | -210.43%-25.62B | -635.38%-23.59B | -101.93%-308M | -164.48%-1.3B | -150.60%-425M | -30.79%23.2B | -48.35%4.41B | -13.37%15.94B | -69.67%2.02B |
Less:Other special charges | -3,448.83%-10.01B | 57.13%-12.64B | -34.26%-14.01B | 99.99%-2M | 153.98%1.07B | 134.29%299M | -59.44%-29.49B | 13.31%-10.43B | -12,278.95%-16.2B | 70.15%-1.98B |
Less:Write off | ---- | 508.70%38.26B | 523.72%37.6B | --310M | --229M | 293.75%126M | 141.83%6.29B | 71.93%6.03B | ---- | ---- |
Other non-operating income (expenses) | 969.05%898M | -59.61%206M | 17.56%1.03B | 35.72%-754M | -209.15%-155M | -87.35%84M | -78.71%510M | -65.09%877M | -663.94%-1.17B | 265.12%142M |
Income before tax | 19.38%94.32B | 19.44%143.01B | -50.21%16.17B | -36.40%30.44B | 9.24%17.4B | 236.57%79.01B | -5.64%119.73B | 1.14%32.48B | -7.55%47.86B | -31.61%15.93B |
Income tax | 50.06%30.16B | 5.10%31.56B | -55.20%4.67B | -24.27%8.2B | -172.69%-1.41B | 193.53%20.1B | 13.79%30.03B | 269.22%10.41B | -30.30%10.83B | -53.83%1.94B |
Net income | 8.92%64.16B | 24.25%111.45B | -47.85%11.51B | -39.95%22.23B | 34.42%18.81B | 254.30%58.91B | -10.74%89.7B | -24.68%22.06B | 2.21%37.02B | -26.73%13.99B |
Net income continuous operations | 8.92%64.16B | 24.25%111.45B | -47.86%11.51B | -39.95%22.23B | 34.42%18.81B | 254.30%58.91B | -10.74%89.71B | -24.67%22.07B | 2.21%37.02B | -26.73%13.99B |
Noncontrolling interests | 1.88%868M | -86.94%524M | -206.00%-865M | -118.55%-95M | -64.81%632M | -3.95%852M | 20.85%4.01B | -50.87%816M | 6.00%512M | 1,022.50%1.8B |
Net income attributable to the company | 9.02%63.29B | 29.45%110.93B | -41.78%12.37B | -38.84%22.33B | 49.04%18.17B | 268.87%58.06B | -11.82%85.69B | -23.10%21.25B | 2.16%36.51B | -35.60%12.19B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 9.02%63.29B | 29.45%110.93B | -41.78%12.37B | -38.84%22.33B | 49.04%18.17B | 268.87%58.06B | -11.82%85.69B | -23.10%21.25B | 2.16%36.51B | -35.60%12.19B |
Gross dividend payment | ||||||||||
Basic earnings per share | 18.76%133.675 | 37.91%221.56 | -33.07%26.875 | -33.25%45.6604 | 58.17%36.0705 | 284.29%112.56 | -9.70%160.655 | -21.50%40.155 | 4.20%68.405 | -33.94%22.805 |
Diluted earnings per share | 18.76%133.67 | 37.91%221.525 | -33.09%26.865 | -33.24%45.6604 | 58.20%36.0705 | 284.39%112.55 | -9.70%160.63 | -21.49%40.15 | 4.20%68.4 | -33.94%22.8 |
Dividend per share | 0 | 0.00%32 | 0.00%16 | 0 | 0.00%16 | 0 | 0.00%32 | 0.00%16 | 0 | 0.00%16 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |